Viking Therapeutics' late-stage obesity drug and promising weight-maintenance data could offer greater upside than Novo Nordisk, despite higher clinical and commercial risks.

Bristol-Myers Squibb (BMY -0.91%) earns most of its revenue by commercializing complex prescription medications for cancer, cardiovascular conditions, and immunological diseases.

Carnegie Investment Counsel lowered its position in Novo Nordisk A/S (NYSE: NVO) by 28.6% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 121,560 shares of the company's stock after selling 48,696 shares during the quarter. Carnegie Investment Counsel's holdings

Novo remains a leader in the diabetes and weight loss drug markets. The company could make significant clinical and regulatory progress over the next few years.

NVO's Ozempic and Wegovy sales will be in focus for Q3 results as oral GLP-1 launches expand, while pricing pressure and competition challenge growth.

Novo Nordisk's CagriSema delivers 25% weight loss in women, spotlighting three ETFs for diversified exposure to the sector's growth.

Its leading investigational drug demonstrated relatively high levels of weight loss in a late-stage clinical trial.

A European regulatory endorsement for an oral obesity pill is lifting Eli Lilly (NYSE:LLY | LLY Price Prediction) stock ahead of the rest of the drug group. Eli Lilly stock is up 4% to $1,295.